logo-loader
viewSareum Holdings PLC

Sareum Holdings poster details released

Sareum Holdings' chief executive, Dr Tim Mitchell, will outline the potential of the company’s latest drug to fight a number of cancers when he attends the American Association for Cancer Research on October 29

Sareum Holdings PLC -

Sareum Holdings PLC’s (LON:SAR) chief executive, Dr Tim Mitchell, will outline the potential of the company’s latest drug to fight a number of cancers when he attends a US conference later this month.

In lab models, SDC-1802, a TYK2/JAK1 inhibitor, significantly reduced tumour growth in cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma.

Saruem believes it may have developed a “potentially powerful” immunotherapy that will help combat the killer diseases.

Mitchell will give a poster presentation to the American Association for Cancer Research on October 29 outlining the latest findings. The poster is now available on the AACR website [click here].

"We are looking forward to presenting the data showing how our TYK2/JAK1 inhibitor, SDC-1802, induces a significant reduction of tumour growth in preclinical models of many cancer types via a novel immunotherapeutic mechanism of action,” said Mitchell.

“These data suggest that our TYK2/JAK1 inhibitor could also offer the additional potential advantage of oral delivery.

“This contrasts with currently marketed cancer immunotherapies, which can only be dosed by injection.

“We are delighted to be presenting at this important international cancer conference and engaging with interested parties from the many leading pharma and biotech companies that attend this event."

Quick facts: Sareum Holdings PLC

Price: 0.885 GBX

AIM:SAR
Market: AIM
Market Cap: £28.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

2 days, 18 hours ago

2 min read